159 research outputs found
Die schönsten Schweizer Volkslieder = Nos plus belles chansons populaires
No full textMax Peter Baumann, Texte und Liedauswahl. Emil Zbinden, Holzschn. Georg Stärk, Foto
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
No full textBACKGROUND
No data are available on the long-term performance of ultrathin strut biodegradable polymer sirolimus-eluting stents (BP-SES). We reported 2-year clinical outcomes of the BIOSCIENCE (Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularisation) trial, which compared BP-SES with durable-polymer everolimus-eluting stents (DP-EES) in patients undergoing percutaneous coronary intervention.
METHODS AND RESULTS
A total of 2119 patients with minimal exclusion criteria were assigned to treatment with BP-SES (n=1063) or DP-EES (n=1056). Follow-up at 2 years was available for 2048 patients (97%). The primary end point was target-lesion failure, a composite of cardiac death, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. At 2 years, target-lesion failure occurred in 107 patients (10.5%) in the BP-SES arm and 107 patients (10.4%) in the DP-EES arm (risk ratio [RR] 1.00, 95% CI 0.77-1.31, P=0.979). There were no significant differences between BP-SES and DP-EES with respect to cardiac death (RR 1.01, 95% CI 0.62-1.63, P=0.984), target-vessel myocardial infarction (RR 0.91, 95% CI 0.60-1.39, P=0.669), target-lesion revascularization (RR 1.17, 95% CI 0.81-1.71, P=0.403), and definite stent thrombosis (RR 1.38, 95% CI 0.56-3.44, P=0.485). There were 2 cases (0.2%) of definite very late stent thrombosis in the BP-SES arm and 4 cases (0.4%) in the DP-EES arm (P=0.423). In the prespecified subgroup of patients with ST-segment elevation myocardial infarction, BP-SES was associated with a lower risk of target-lesion failure compared with DP-EES (RR 0.48, 95% CI 0.23-0.99, P=0.043, Pinteraction=0.026).
CONCLUSIONS
Comparable safety and efficacy profiles of BP-SES and DP-EES were maintained throughout 2 years of follow-up.
CLINICAL TRIAL REGISTRATION
URL: https://www.clinicaltrials.gov. Unique identifier: NCT01443104
Herausforderungen und Zukunftsperspektiven in der Arbeitsintegration
No full textDie Arbeitswelt hat sich in den letzten Jahrzehnten stark verändert und verlangt zunehmend nach gut ausgebildeten Fachkräften. Gleichzeitig haben die Anforderungen der Geldgeber*innen zugenommen. Wie können sich die Anbieter*innen von Integrationsmassnahmen in diesem Spannungsfeld behaupten? Der Leiter des Kompetenzzentrums Arbeit der Stadt Bern liefert Antworten
Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients
No full textOBJECTIVE
Due to reduction of immune-suppressive drugs, patients with rheumatic diseases can experience an increase in disease activity during pregnancy. In such cases, TNF-inhibitors may be prescribed. However, monoclonal antibodies with the Fc moiety are actively transported across the placenta, resulting in therapeutic drug levels in the newborn. As certolizumab (CZP) lacks the Fc moiety, it may bear a lower risk for the child.
METHOD
We report a case series of thirteen patients (5 with rheumatoid arthritis and 8 with spondyloarthritis) treated with CZP during late pregnancy to control disease activity.
RESULT
CZP measured in cord blood of eleven infants ranged between undetectable levels and 1μg/mL whereas the median CZP level of maternal plasma was 32.97μg/mL. Three women developed an infection during the third trimester, of whom one had a severe infection and one had an infection that resulted in a pre-term delivery. During the postpartum period, 6 patients remained on CZP while breastfeeding. CZP levels in the breast milk of two breastfeeding patients were undetectable.
CONCLUSION
The lack of the active transplacental transfer of CZP gives the possibility to treat inflammatory arthritis during late gestation without potential harm to the newborn. However, in pregnant women treated with TNF-inhibitors and prednisone, attention should be given to the increased susceptibility to infections, which might cause prematurity. CZP treatment can be continued while breastfeeding
Employment relations, job security and emigration intentions: “The individualization of the social”?
No full textThis study uses the UNDP/UNICEF Social Exclusion Survey in Macedonia and Serbia and focus on the questions of (i) why are there sometimes no differences in emigration intentions between unemployed and employed groups, and (ii) why many gainfully employed individuals still intend to migrate to another country for employment. This research differs from the majority of studies, which do not distinguish between various types of jobs and variation in emigration intentions stemming from employment stratification. Employment sectors and individuals’ occupations have been taken as the main forms of job segregation, but since the 1990s some scholars have claimed that traditional labour market stratification is losing its relevance. We contribute to the migration literature by testing the “individualization hypothesis” – that specific characteristics of employees serve as better covariates of emigration intentions than “umbrella” concepts of industry and social class. Our findings suggest that emigration intentions among employed individuals are more likely to be affected by the type of contract and job security than by standard job-related variables such as sector and occupation of employment
Übersetzung und Interpretation. Jacob Peter Mayer, Hans Zbinden und die deutsche Übersetzung von Tocquevilles „De la Démocratie en Amérique“ (1959/62)
No full textRisk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: disease activity matters.
No full textObjective
To analyse pregnancy outcome and delivery mode in patients with RA and axial spondyloarthritis (axSpA) in relation to disease activity and anti-rheumatic drugs.
Methods
Patients with RA and axSpA were compared with age-matched healthy controls (HCs) with respect to pregnancy outcome and delivery mode. Disease activity (DAS28, ASDAS, CRP) and medication use of patients was assessed once at each trimester. ORs with 95% CI were calculated with univariate and multivariate regression models.
Results
We analysed 244 pregnancies, of which 96 occurred in patients with RA, 78 in patients with axSpA and 70 in HCs. The adjusted analysis showed that pregnant women with RA and axSpA had a higher risk of pregnancy complications (gestational diabetes, preeclampsia, infection, preterm premature rupture of membranes), small for gestational age infants and preterm deliveries (all P < 0.05). Active disease was a predictor for preterm delivery in both RA [odds ratio (OR) = 3.9, 95% CI: 1.25, 12.15] and axSpA (OR = 13.8, 95% CI: 1.33, 143.94). Regarding delivery mode, most patients had vaginal deliveries. However, women with RA revealed an increased risk of caesarean section compared with HC (P < 0.05), which was not seen in patients with axSpA.
Conclusion
Our findings show that disease activity of RA and axSpA during pregnancy influences pregnancy outcome. To allow for successful pregnancy a treatment strategy that targets inactive disease beyond conception should be followed
- …
